Literature DB >> 21345729

5-HT(3) receptors: potential of individual isoforms for personalised therapy.

Beate Niesler1.   

Abstract

Serotonin type 3 (5-HT(3)) receptors are ligand-gated ion channels built by five subunits of diverse composition. In humans, five subunits exist (5-HT3A-E) which are encoded by the genes HTR3A-E and are expressed in various isoforms. Recently, the importance of factors influencing receptor expression became clear, such as chaperones and microRNAs. Owing to their expression profile and physiological functions, 5-HT(3) receptors have been implicated in irritable bowel syndrome (IBS) and psychiatric disorders. Interestingly, HTR3 variants have now been shown to be associated with these conditions. This underlines the potential of 5-HT(3) receptors as therapeutic targets and may enable personalised therapies in the future.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21345729     DOI： 10.1016/j.coph.2011.01.011

Source DB:  PubMed          Journal:  Curr Opin Pharmacol        ISSN： 1471-4892            Impact factor:   5.547


  13 in total

1.  Delineating the Site of Interaction of the 5-HT3A Receptor with the Chaperone Protein RIC-3.

Authors:  Elham Pirayesh; Antonia G Stuebler; Akash Pandhare; Michaela Jansen
Journal:  Biophys J       Date:  2019-11-28       Impact factor: 4.033

2.  Orthosteric and Allosteric Activation of Human 5-HT3A Receptors.

Authors:  Noelia Rodriguez Araujo; Camila Fabiani; Albano Mazzarini Dimarco; Cecilia Bouzat; Jeremías Corradi
Journal:  Biophys J       Date:  2020-09-02       Impact factor: 4.033

3.  Interlaboratory reproducibility of selective reaction monitoring assays using multiple upfront analyte enrichment strategies.

Authors:  Amol Prakash; Taha Rezai; Bryan Krastins; David Sarracino; Michael Athanas; Paul Russo; Hui Zhang; Yuan Tian; Yan Li; Vathany Kulasingam; Andrei Drabovich; Christopher R Smith; Ihor Batruch; Paul E Oran; Claudia Fredolini; Alessandra Luchini; Lance Liotta; Emanuel Petricoin; Eleftherios P Diamandis; Daniel W Chan; Randall Nelson; Mary F Lopez
Journal:  J Proteome Res       Date:  2012-07-03       Impact factor: 4.466

Review 4.  Partial agonism of 5-HT3 receptors: a novel approach to the symptomatic treatment of IBS-D.

Authors:  Nicholas A Moore; Bruce J Sargent; David D Manning; Peter R Guzzo
Journal:  ACS Chem Neurosci       Date:  2012-12-10       Impact factor: 4.418

5.  Novel mechanism of modulation at a ligand-gated ion channel; action of 5-Cl-indole at the 5-HT3 A receptor.

Authors:  Andrew D Powell; Gillian Grafton; Alexander Roberts; Shannon Larkin; Nathanael O'Neill; Josephine Palandri; Reka Otvos; Alison J Cooper; Chris Ulens; Nicholas M Barnes
Journal:  Br J Pharmacol       Date:  2016-11-01       Impact factor: 8.739

6.  Agonists and antagonists induce different palonosetron dissociation rates in 5-HT₃A and 5-HT₃AB receptors.

Authors:  Sarah C R Lummis; Andrew J Thompson
Journal:  Neuropharmacology       Date:  2013-06-05       Impact factor: 5.250

Review 7.  Discriminating between 5-HT₃A and 5-HT₃AB receptors.

Authors:  A J Thompson; S C R Lummis
Journal:  Br J Pharmacol       Date:  2013-06       Impact factor: 8.739

Review 8.  5-HT(3) receptors.

Authors:  Sarah C R Lummis
Journal:  J Biol Chem       Date:  2012-10-04       Impact factor: 5.157

9.  Replication of functional serotonin receptor type 3A and B variants in bipolar affective disorder: a European multicenter study.

Authors:  C Hammer; S Cichon; T W Mühleisen; B Haenisch; F Degenhardt; M Mattheisen; R Breuer; S H Witt; J Strohmaier; L Oruc; F Rivas; G Babadjanova; M Grigoroiu-Serbanescu; J Hauser; R Röth; G Rappold; M Rietschel; M M Nöthen; B Niesler
Journal:  Transl Psychiatry       Date:  2012-04-17       Impact factor: 6.222

10.  The Concise Guide to PHARMACOLOGY 2013/14: ligand-gated ion channels.

Authors:  Stephen P H Alexander; Helen E Benson; Elena Faccenda; Adam J Pawson; Joanna L Sharman; Michael Spedding; John A Peters; Anthony J Harmar
Journal:  Br J Pharmacol       Date:  2013-12       Impact factor: 8.739
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.